Phase 2 N=4 TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=364 Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
Knee Osteoarthritis
Primary: Primary Endpoint: WOMAC Pain Score (Likert Scale Version) at 4 Weeks — 8.08; 6.73 units on a scale
Phase 2 N=27 A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
AL Amyloidosis
Primary: Assessing Dose-limiting Toxicity to Determine Maximal Tolerated Dosage at 2 Milligram Dose — 0 Participants
Phase 2 N=48 Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) — 0; 0; 0; 0 Participants
Phase 2 N=81 High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
Lymphoma
Primary: Event-free Survival (EFS) of Patients — 51 Participants
Phase 2 N=25 NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Donor Neutrophil Engraftment — 3; 7; 1 Participants
Phase 2 N=118 Prostaglandin Inhibition for Emphysema
Emphysema
Primary: Will Ibuprofen, 600 mg Three Times Daily, Decrease PGE Concentration in the Alveolar Portion of BAL Fluid in Subjects With Emphysema in Comparison to Placebo? — 0.003…
Phase 2 N=25 Rituximab in Pretreated Elderly or Unfit B-CLL Patients
B-Cell Chronic Lymphocytic Leukemia
Primary: Overall Response Rate — 7 Participants
Phase 2 N=43 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Adult B Acute Lymphoblastic Leukemia · Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Adult Solid Neoplasm
Primary: Maximum Tolerated Dose of Veliparib When Combined With Bendamustine Hydrochloride — 300 mg
Phase 2 N=20 Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
X-Linked Hypophosphatemia
Primary: Number of Participants With Adverse Events (AEs), Treatment Emergent AEs (TEAEs), Serious AEs (SAEs), and AEs Leading to Discontinuation or Death — 20; 20; 12; 9…
Phase 2 N=24 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Metastatic Ureter Carcinoma · Metastatic Urethral Carcinoma · Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Primary: Observed Overall Response Rate — 50 percentage of participants
Phase 2 N=20 Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Graft Versus Host Disease · Leukemia · Lymphoma
Primary: Overall Response Rate — 12; 1; 7 Participants
Phase 2 N=103 Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression Free Survival — 7.33; 9.13 Months — p=0.046
Phase 2 N=23 Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
Myasthenia Gravis
Primary: Proportion of Patients Whose Quantitative Myasthenia Gravis Scores Are Increased by no More Than 3 Points at the End of the SCIg Treatment Phase — 0.864 proportion of…
Phase 2 N=116 Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.
Asthma
Primary: Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment Period — 2.792; 2.779…